Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2023 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The question asks if a substantial part of the forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies or serves, such that the company's own coming volume is a consequence of those parties' trajectories. Let's analyze the transcript. Rich Gelfond and Natasha Fernandes discuss results and outlook. They mention signings, installations, box office, and various deals. They talk about local language films, China, Japan, etc. They mention specific deals like Kinopolis doubling its IMAX footprint, Aon signings, and other exhibitors. They also discuss the impact of Oppenheimer and how it might drive further growth. They talk about the strike and potential content shifts. Key points: Management speaks about counterparties' business? They mention exhibitors signing deals, installing systems, and the growth of the IMAX network. They say "We're seeing exhibitors bring more IMAX to their existing multiplexes globally" and cite Kinopolis. They also mention "26 were with exhibition partners who are new to IMAX" and "25% were in U.S. and Canada and 13% in Europe. Nearly half were in Japan and Southeast Asia, including the seven Aon signings from January, which are all installed and off to a strong start." They talk about the ramp of installations and signings. They also discuss the box office performance and how it drives demand. But is the forward account primarily about counterparties' own trajectories? They talk about their own signings and installations, which are results of their selling efforts. They also talk about the box office and content slate. They mention that the success of Oppenheimer might lead to more demand, but that's more about market trends.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.